SCHEMBL23528889

SCHEMBL23528889

Cc1ncc(Cl)nc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
TDP1 Q9NUW8 1/20 0.44
ALDH1A1 P00352 4/20 0.40
MAPK1 P28482 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GRM5 P41594 3/20 0.39
NAPRT Q6XQN6 1/20 0.38
SIRT6 Q8N6T7 1/20 0.38
KDM4E B2RXH2 2/20 0.38
ATM Q13315 1/20 0.37
HPGD P15428 2/20 0.37
HCAR2 Q8TDS4 2/20 0.37
TSHR P16473 1/20 0.37
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PKM P14618 2/20 0.36
KMO O15229 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29948993 0.84 KMT2A (0.47) KMT2AMEN1TDP1ALDH1A1MAPK1
SCHEMBL479985 0.84 KMT2A (0.47) KMT2AMEN1TDP1ALDH1A1MAPK1
SCHEMBL2253990 0.82 SIRT6 (0.46) KMT2AMEN1ALDH1A1GRM5SIRT6
SCHEMBL20046666 0.81 MEN1 (0.47) KMT2AMEN1TDP1ALDH1A1MAPK1
SCHEMBL361702 0.79 NPSR1 (0.47) ALDH1A1MAPK1SMN1; SMN2GRM5KDM4E
SCHEMBL2408636 0.79 KDM4E (0.40) KMT2AMEN1TDP1ALDH1A1MAPK1
SCHEMBL6377192 0.79 MEN1 (0.46) KMT2AMEN1TDP1ALDH1A1MAPK1
SCHEMBL10335107 0.78 ALOX15 (0.46) KMT2AMEN1TDP1ALDH1A1MAPK1
SCHEMBL2407807 0.77 ALDH1A1 (0.51) KMT2AMEN1ALDH1A1MAPK1KDM4E
SCHEMBL28504710 0.76 KDM4E (0.38) KMT2AMEN1TDP1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070879-A1 ISOXAZOLINE DERIVATIVES ELANCO TIERGESUNDHEIT AG (CH) 2026-03-12 US disclosed
US-12497370-B2 Isoxazoline derivatives ELANCO TIERGESUNDHEIT AG (CH) 2025-12-16 US disclosed
CN-120004816-A Isoxazoline derivatives 礼蓝动物保健有限公司 2025-05-16 CN disclosed
US-20250145596-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. 2025-05-08 US disclosed
CN-115210221-B Isoxazoline derivatives as pesticides 礼蓝动物保健有限公司 2025-03-18 CN disclosed
EP-4476213-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2024-12-18 EP disclosed
CN-119072474-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2024-12-03 CN disclosed
US-20240124431-A1 2,3-DIHYDRO-4H-BENZO[B][1,4]OXAZIN-4-YL)(5-(PHENYL)-PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP11A1 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER ORION CORPORATION (FI) 2024-04-18 US disclosed
US-11760762-B2 Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors SIGNALRX PHARMACEUTICALS, INC. (US) 2023-09-19 US disclosed
WO-2023151575-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO INC. (US) 2023-08-17 WO disclosed
EP-4077286-A1 ISOXAZOLINE DERIVATIVES AS PESTICIDES Elanco Tiergesundheit AG (CH) 2022-10-26 EP disclosed
CN-115210221-A Isoxazoline derivatives as pesticides 礼蓝动物保健有限公司 2022-10-18 CN disclosed
US-20210188789-A1 ISOXAZOLINE DERIVATIVES ELANCO TIERGESUNDHEIT AG 2021-06-24 US disclosed
WO-2021127188-A1 ISOXAZOLINE DERIVATIVES AS PESTICIDES ELANCO TIERGESUNDHEIT AG (CH) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11760762-B2 Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors CDK1, CDKN1A, CDKL1 KMT2A 1487/4885MEN1 750/4885TDP1 609/4885
US-12497370-B2 Isoxazoline derivatives CYP3A7, CYP4X1, CYP2A7 KMT2A 1360/4885MEN1 4188/4885TDP1 1915/4885
US-20260070879-A1 ISOXAZOLINE DERIVATIVES CHRM1, CBR3, AFF1 KMT2A 1987/4885MEN1 1644/4885TDP1 2994/4885
US-20240124431-A1 2,3-DIHYDRO-4H-BENZO[B][1,4]OXAZIN-4-YL)(5-(PHENYL)-PYRIDIN-3-YL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS AS CYP11A1 INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER CYP11B1, CYP11B2, SRD5A1 KMT2A 2136/4885MEN1 1386/4885TDP1 3108/4885
US-20250145596-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR KMT2A 3661/4885MEN1 425/4885TDP1 2997/4885
US-20210188789-A1 ISOXAZOLINE DERIVATIVES CYP3A7, CYP4X1, SIRT7 KMT2A 1656/4885MEN1 4136/4885TDP1 1807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.